Immune durability and protection against SARS-CoV-2 re-infection in Syrian hamsters

References

• Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141–154.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720.
   PubMed Web of Science ®Google Scholar
• Alfego D, Sullivan A, Poirier B, et al. A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States. EClinicalMedicine. 2021;36:100902.
   PubMedGoogle Scholar
• Chen Y, Zuiani A, Fischinger S, et al. Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production. Cell. 2020;183:1496–1507.e16.
   PubMed Web of Science ®Google Scholar
• Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:1–13.
   Web of Science ®Google Scholar
• Rodda LB, Netland J, Shehata L, et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell. 2021;184:169–183.e17.
   PubMed Web of Science ®Google Scholar
• Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5:1598–1607.
   PubMed Web of Science ®Google Scholar
• Turner JS, Kim W, Kalaidina E, et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature. 2021;595:421–425.
   PubMed Web of Science ®Google Scholar
• Gaunt ER, Hardie A, Claas EC, et al. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol. 2010;48:2940–2947.
   PubMed Web of Science ®Google Scholar
• Gorse GJ, Donovan MM, Patel GB. Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses. J Med Virol. 2020;92:512–517.
   PubMed Web of Science ®Google Scholar
• Liu P, Shi L, Zhang W, et al. Prevalence and genetic diversity analysis of human coronaviruses among cross-border children. Virol J. 2017;14:230.
   PubMed Web of Science ®Google Scholar
• Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370:1227–1230.
   PubMed Web of Science ®Google Scholar
• Zhang SF, Tuo JL, Huang XB, et al. Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in Guangzhou. PLoS One. 2018;13:e0191789.
   PubMed Web of Science ®Google Scholar
• Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). The Lancet. 2021;397:1459–1469.
   PubMed Web of Science ®Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Coyle P, et al. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine. 2021;35:100861.
   PubMedGoogle Scholar
• Tillett RL, Sevinsky JR, Hartley PD, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2021;21:52–58.
   PubMed Web of Science ®Google Scholar
• To KK, Hung IF, Ip JD, et al. Coronavirus Disease 2019 (COVID-19) Re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing. Clin Infect Dis. 2021;73:e2946–e2e51.
   PubMed Web of Science ®Google Scholar
• Vitale J, Mumoli N, Clerici P, et al. Assessment of SARS-CoV-2 reinfection 1 year After primary infection in a population in Lombardy, Italy. JAMA Intern Med. 2021;181:1407–1408.
   PubMed Web of Science ®Google Scholar
• West J, Everden S, Nikitas N. A case of COVID-19 reinfection in the UK. Clin Med (Lond). 2021;21:e52–e53.
   PubMed Web of Science ®Google Scholar
• Chan JF, Zhang AJ, Yuan S, et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease Pathogenesis and transmissibility. Clin Infect Dis. 2020;71:2428–2446.
   PubMed Web of Science ®Google Scholar
• Rosenke K, Meade-White K, Letko M, et al. Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection. Emerg Microbes Infect. 2020;9:2673–2684.
   PubMed Web of Science ®Google Scholar
• Sia SF, Yan LM, Chin AWH, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020;583:834–838.
   PubMed Web of Science ®Google Scholar
• Patel DR, Field CJ, Septer KM, et al. Transmission and protection against reinfection in the ferret model with the SARS-CoV-2 USA-WA1/2020 Reference isolate. J Virol. 2021;95:e0223220.
   PubMed Web of Science ®Google Scholar
• Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27:493–497.
   Google Scholar
• Dhakal S, Ruiz-Bedoya CA, Zhou R, et al. Sex differences in lung imaging and SARS-CoV-2 antibody responses in a COVID-19 golden syrian hamster model. mBio. 2021;12:e0097421.
   PubMed Web of Science ®Google Scholar
• Gerhards NM, Cornelissen J, van Keulen LJM, et al. Predictive value of precision-cut lung slices for the susceptibility of three animal species for SARS-CoV-2 and validation in a refined hamster model. Pathogens. 2021;10:824–846.
   PubMed Web of Science ®Google Scholar
• Osterrieder N, Bertzbach LD, Dietert K, et al. Age-dependent progression of SARS-CoV-2 infection in Syrian hamsters. Viruses. 2020;12:779–790.
   PubMed Web of Science ®Google Scholar
• Imai M, Iwatsuki-Horimoto K, Hatta M, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A. 2020;117:16587–16595.
   PubMed Web of Science ®Google Scholar
• Brustolin M, Rodon J, Rodriguez de la Concepcion ML, et al. Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster. Emerg Microbes Infect. 2021;10:797–809.
   PubMed Web of Science ®Google Scholar
• Yinda CK, Port JR, Bushmaker T, et al. Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant. Emerg Microbes Infect. 2021;10:1284–1292.
   PubMed Web of Science ®Google Scholar
• Cohen KW, Linderman SL, Moodie Z, et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep Med. 2021;2:100354–100375.
   PubMedGoogle Scholar
• Horiuchi S, Oishi K, Carrau L, et al. Immune memory from SARS-CoV-2 infection in hamsters provides variant-independent protection but still allows virus transmission. Sci Immunol. 2021;6:1–14.
   Web of Science ®Google Scholar
• Davidson AD, Williamson MK, Lewis S, et al. Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein. Genome Med. 2020;12:68–83.
   PubMed Web of Science ®Google Scholar
• Klimstra WB, Tilston-Lunel NL, Nambulli S, et al. SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients. J Gen Virol. 2020;101:1156–1169.
   PubMed Web of Science ®Google Scholar